[go: up one dir, main page]

MX2022013911A - Peptidos y metodos para el tratamiento de esclerosis multiple. - Google Patents

Peptidos y metodos para el tratamiento de esclerosis multiple.

Info

Publication number
MX2022013911A
MX2022013911A MX2022013911A MX2022013911A MX2022013911A MX 2022013911 A MX2022013911 A MX 2022013911A MX 2022013911 A MX2022013911 A MX 2022013911A MX 2022013911 A MX2022013911 A MX 2022013911A MX 2022013911 A MX2022013911 A MX 2022013911A
Authority
MX
Mexico
Prior art keywords
treatment
peptides
methods
multiple sclerosis
cells
Prior art date
Application number
MX2022013911A
Other languages
English (en)
Inventor
Jean- Marie Saint-Remy
Vincent Carlier
Elst Luc Vander
Milos Erak
Rampelbergh Jean Van
Mechelen Marcelle Van
David Walgraffe
Geoffrey Gloire
Original Assignee
Imcyse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa filed Critical Imcyse Sa
Publication of MX2022013911A publication Critical patent/MX2022013911A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)

Abstract

La invención se relaciona con péptidos inmunogénicos derivados de la Glicoproteína de Mielina de Oligodendrocitos (MOG) para uso en el tratamiento de trastornos de desmielinización y la generación de células T CD4+ citolíticas o células NKT contra células presentadoras de antígenos que presentan la secuencia del epítope MOG de tipo salvaje.
MX2022013911A 2020-05-06 2021-05-06 Peptidos y metodos para el tratamiento de esclerosis multiple. MX2022013911A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20173201 2020-05-06
PCT/EP2021/061985 WO2021148683A2 (en) 2020-05-06 2021-05-06 Peptides and methods for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
MX2022013911A true MX2022013911A (es) 2022-11-30

Family

ID=70613608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013911A MX2022013911A (es) 2020-05-06 2021-05-06 Peptidos y metodos para el tratamiento de esclerosis multiple.

Country Status (17)

Country Link
US (1) US20230340061A1 (es)
EP (1) EP4146676A2 (es)
JP (1) JP2023525084A (es)
KR (1) KR20230006905A (es)
CN (1) CN115702162A (es)
AR (1) AR122023A1 (es)
AU (1) AU2021210629A1 (es)
CA (1) CA3181368A1 (es)
CO (1) CO2022017087A2 (es)
CU (1) CU20220066A7 (es)
IL (1) IL297945A (es)
MX (1) MX2022013911A (es)
PE (1) PE20240491A1 (es)
PH (1) PH12022552979A1 (es)
TW (1) TW202208413A (es)
WO (1) WO2021148683A2 (es)
ZA (1) ZA202212773B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2059256T3 (en) 2006-08-11 2016-12-05 Life Sciences Res Partners Vzw Immunogenic peptides AND USE THEREOF FOR THE IMMUNE DISORDERS
EP3915575A1 (en) * 2020-05-29 2021-12-01 Imnate Sarl Vaccine formulations
WO2025105734A1 (ko) * 2023-11-15 2025-05-22 주식회사 카인사이언스 탈수초 질환 치료용 펩타이드 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2059256T3 (en) 2006-08-11 2016-12-05 Life Sciences Res Partners Vzw Immunogenic peptides AND USE THEREOF FOR THE IMMUNE DISORDERS
AU2009214041A1 (en) 2008-02-14 2009-08-20 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
CN103261218B (zh) * 2010-11-25 2020-08-14 Imnate责任有限公司 免疫原性肽在预防和/或治疗疾病中的应用
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
CY1120669T1 (el) * 2012-08-03 2019-12-11 Fwp Ip Aps Συνδυαστικη θεραπεια για αγωγη σκληρυνσης κατα πλακας
CN105682648A (zh) * 2013-08-26 2016-06-15 前进制药公司 用于以低的日剂量施用的含富马酸二甲酯的药物组合物
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US11787849B2 (en) * 2015-09-25 2023-10-17 Imcyse Sa Methods and compounds for eliminating immune responses to therapeutic agents
SG11201808710UA (en) * 2016-04-19 2018-11-29 Imcyse Sa Novel immunogenic cd1d binding peptides
EP3607058A4 (en) * 2017-04-07 2020-12-16 UTI Limited Partnership ASSAY FOR MEASURING THE POWER OF LIGAND-RECEPTOR INTERACTIONS IN NANOMEDUCINES

Also Published As

Publication number Publication date
CA3181368A1 (en) 2021-07-29
WO2021148683A3 (en) 2021-09-23
CN115702162A (zh) 2023-02-14
WO2021148683A2 (en) 2021-07-29
ZA202212773B (en) 2024-04-24
TW202208413A (zh) 2022-03-01
AU2021210629A1 (en) 2022-12-08
AR122023A1 (es) 2022-08-03
IL297945A (en) 2023-01-01
US20230340061A1 (en) 2023-10-26
CU20220066A7 (es) 2023-06-13
KR20230006905A (ko) 2023-01-11
EP4146676A2 (en) 2023-03-15
PH12022552979A1 (en) 2024-02-26
CO2022017087A2 (es) 2023-02-16
JP2023525084A (ja) 2023-06-14
PE20240491A1 (es) 2024-03-15

Similar Documents

Publication Publication Date Title
CO2022017087A2 (es) Péptidos y métodos para el tratamiento de esclerosis múltiple
BR112021025035A2 (pt) Composições e métodos para imunoterapia contra câncer
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
BR112021019558A2 (pt) Composições e métodos para preparar composições de células t e usos dos mesmos
DOP2011000114A (es) “compuestos de 9h-purin-6-aminoalquilo que expanden las celulas madre hematopoyeticas
MX2016016236A (es) Anticuerpos dirigidos contra cd127.
BR112022019609A2 (pt) Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
PE20211307A1 (es) ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS
PE20211494A1 (es) Peptidos inmunogenicos con motivos de oxidorreductasa mejorados
BR112023001642A2 (pt) Bancos de células t específicos de antígeno universais e métodos de preparar e usar os mesmos automaticamente
CL2021000532A1 (es) Vacunas peptídicas
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения
MX2021005372A (es) Composiciones de linfocitos t con propiedades fenotípicas mejoradas.
MX2021012994A (es) Administracion heterologa de vacunas tau.
BR112021025477A2 (pt) Formulações de lisofosfatidilcolina parenteral como lpc-dha, lpc-epa e seus usos em terapia
DOP2020000082A (es) Administración oral de análogos del péptido glp-1
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
CL2021000485A1 (es) Una cepa mutante de salmonella enteritidis; procedimiento para generar la cepa mutante; vacuna recombinante aviar de salmonella enteritidis, divisional de la solicitud 201903108
MX2018016091A (es) Composiciones de fosfolipidos.
CO2024000603A2 (es) Péptidos y métodos para el tratamiento de neuromielitis óptica
MX2021009662A (es) Anticuerpos anti-adresina de ganglios linfaticos perifericos y usos de los mismos.
BR112021018684A2 (pt) Métodos para aumentar a eficiência de esgotamento de células tcr¿¿+
MX2021001357A (es) Peptido derivado de cdca1 y vacuna que lo contiene.
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.